ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 75.89 |
| Open | 75.95 |
| Bid | 75.06 x 1400 |
| Ask | 75.13 x 800 |
| Day's Range | 74.92 - 75.95 |
| 52 Week Range | 60.27 - 124.22 |
| Volume | 126,630 |
| Avg. Volume | 950,525 |
| Market Cap | 8.003B |
| Beta (3Y Monthly) | 2.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.87 |
| Earnings Date | Jul 31, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 121.61 |
- Zacks•2 hours ago
Horizon's NDA for Procysbi New Dosage Form Accepted by FDA
The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.
- Business Wire•3 days ago
Alnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, and 23andMe, the leading consumer genetics company, are collaborating on a program to offer free 23andMe Health + Ancestry kits to first-degree family members of 23andMe customers with a TTR variant detected in their Hereditary Amyloidosis (TTR-Related) Genetic Health Risk report.
- Zacks•8 days ago
Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.
- Zacks•8 days ago
Adverum (ADVM) Jumps: Stock Rises 5.1%
Adverum (ADVM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Business Wire•8 days ago
Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that Jeff Poulton is joining the Company on July 11, 2019 and has been appointed Executive Vice President and Chief Financial Officer (CFO), effective August 13, 2019.
- Zacks•9 days ago
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
- Zacks•9 days ago
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
- Zacks•14 days ago
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.
- Zacks•15 days ago
Alnylam (ALNY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Alnylam (ALNY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•17 days ago
Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the sale of part of its royalty interest on future global net sales of ONPATTRO™ (patisiran), an RNA interference (RNAi) therapeutic currently being sold by Alnylam Pharmaceuticals, Inc. (ALNY) (Alnylam), to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada. ONPATTRO utilizes Arbutus’s lipid nanoparticle (LNP) technology, which was licensed to Alnylam in November 2012.
- Zacks•17 days ago
Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.
- Zacks•18 days ago
Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
- Business Wire•18 days ago
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP). Givosiran has been granted Priority Medicines (PRIME) Designation by the EMA as well as Orphan Designation in the European Union.
- Zacks•22 days ago
Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
- Zacks•24 days ago
Alnylam Presents New Data for RNAi Therapeutic Onpattro
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
- Business Wire•25 days ago
Alnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today new results from the Global Open-Label Extension (OLE) study of ONPATTRO® (patisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis. Results were presented at the 2019 Peripheral Nerve Society (PNS) Annual Meeting, being held June 22-26, 2019 in Genoa, Italy.
- Business Wire•28 days ago
Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical and commercial opportunities for RNAi therapeutics, which are currently administered with intravenous or subcutaneous dose administration. The results were presented at the 3rd International Conference on the Long and the Short of Non-Coding RNAs being held June 18-23 in Crete, Greece.
- Insider Monkey•29 days ago
Here’s What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
- Zacks•last month
Alnylam Completes Enrollment in Phase III Study of Lumasiran
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
- Markit•last month
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ALNY are favorable, with net inflows of $4.36 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•last month
Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ONPATTRO® (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. ONPATTRO is the first approved RNAi therapeutic in Japan and Alnylam will launch and directly market it in the country.
- Zacks•last month
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
- Business Wire•last month
Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of adults and children with primary hyperoxaluria type 1 (PH1). Alnylam is on track to report topline results from ILLUMINATE-A expected in late 2019 and, if positive, to submit filings for global regulatory approvals starting in early 2020. “We are pleased to have reached two important milestones for our PH1 program, timely completion of enrollment in ILLUMINATE-A – our Phase 3 pivotal study in adults and children – and successful completion of our Phase 1/2 study with positive final results,” said Pritesh J. Gandhi, PharmD, Vice President and General Manager, Lumasiran program at Alnylam.
- Simply Wall St.•last month
Why Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is A Financially Healthy Company
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Alnylam...
- American City Business Journals•last month
Boston-area biopharm firm has big plans in Philadelphia
Alnylam Pharmaceuticals, a Massachusetts biopharmaceutical company that specializes in RNA interference therapeutics, is expanding its operations into Philadelphia. “We have a small team there now,” said John Maraganore, the CEO of Cambridge, Mass.-based Alnylam. “There’s a lot of competition for talent up here and there is lot of [life sciences industry] talent in the tri-state area there around Philadelphia.
